** Shares of Neurizon Therapeutics fall 26.5% to A$0.125, their lowest level since Jan. 15, 2024
** Stock falls as much as 29.4% in its biggest intraday pct drop since early September 2020
** Biotech firm receives notification from the U.S. FDA that its investigational new drug $(IND.AU)$ application for NUZ-001 to treat amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, has been put under clinical hold
** IND application is a request for authorisation to administer experimental drugs to humans
** Co says FDA has outlined certain concerns over sufficiency of information to assess application
** More than 2.9 mln shares change hands, 7.1 times the 30-day avg
** Neurizon down 26.5% YTD, including current session's moves
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.